The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

Result of AGM

26 May 2017 13:59

RNS Number : 4105G
4d Pharma PLC
26 May 2017
 

4D pharma plc

(the "Company" or "4D")

Result of AGM

At the annual general meeting of 4D pharma plc (AIM: DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, held earlier today, all resolutions put to shareholders were duly passed.

The full text of each resolution was included in the notice of the meeting, which was posted to shareholders on 2 May 2017, and is available on the Company's website www.4dpharmaplc.com.

 

For further information please contact:

4D

+ 44 (0)113 895 0130

Duncan Peyton, Chief Executive Officer

 

Zeus Capital Limited - Nomad and Joint Broker

Dan Bate

+44 (0) 161 831 1512

Dominic Wilson

+44 (0) 203 829 5000

Investec Bank plc - Joint Broker

+44 (0) 207 597 5970

Patrick Robb

Daniel Adams

Carlton Nelson

 

 

About 4D

Founded in February 2014, 4D is a world leader in the development of live biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacteria, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx, that rationally identifies novel bacteria that have a precise and evolved therapeutic effect. All of 4D's live biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. 4D currently has a pipeline of 13 preclinical programmes, covering disease areas such as rheumatoid arthritis, multiple sclerosis and cancer, and is currently conducting subject trials in Irritable Bowel Syndrome and Paediatric Crohn's Disease. The programmes in Paediatric Ulcerative Colitis and Paediatric Crohn's Disease have both been granted Orphan Drug Status by the FDA.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGBDGDUIUDBGRL

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.